Yupelri is not a steroid. It is a long-acting muscarinic antagonist (LAMA), a type of bronchodilator that opens the airways by blocking specific nerve receptors in the lungs. This places it in a completely different drug class from inhaled corticosteroids like fluticasone or budesonide, which work by reducing inflammation. Yupelri’s active ingredient is revefenacin, and it is FDA-approved as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD).
How Yupelri Actually Works
Your airways contain muscarinic receptors that, when activated by certain nerve signals, cause the smooth muscle around the airways to tighten. In COPD, this tightening (bronchoconstriction) is a major contributor to difficulty breathing. Yupelri blocks these receptors, particularly the M3 subtype found on airway smooth muscle, preventing the signal that tells the muscles to contract. The result is relaxed, more open airways.
What makes revefenacin distinctive is its selectivity for the lungs. It binds tightly to the M3 receptor and releases very slowly, with a binding half-life of about 82 minutes at that receptor. This lung selectivity means the drug produces strong bronchodilation locally while minimizing the kind of systemic side effects that can occur when anticholinergic drugs affect other parts of the body. In preclinical testing, a single dose prevented airway constriction for longer than 24 hours, which is why it works as a once-daily medication.
Why People Confuse It With Steroids
The confusion is understandable. Many COPD medications are inhaled corticosteroids, and some combination inhalers bundle a steroid with a bronchodilator. If you’ve been prescribed multiple inhaled medications, it’s easy to assume they all work the same way. But steroids and LAMAs do fundamentally different things.
Inhaled corticosteroids reduce inflammation in the airways over time. They help prevent flare-ups but come with certain risks, including a higher chance of developing pneumonia with long-term use. Yupelri, on the other hand, physically relaxes airway muscles without any anti-inflammatory action. It has a rapid onset and directly improves airflow, measured by a significant increase in the amount of air you can forcefully exhale in one second (FEV1). For many COPD patients, guidelines actually prefer a LAMA like Yupelri over an inhaled steroid as a first-line maintenance option, partly because of the pneumonia risk associated with steroids.
How Yupelri Is Taken
Unlike most LAMAs, which come as dry powder inhalers or metered-dose inhalers, Yupelri is delivered through a standard jet nebulizer. This makes it the first once-daily nebulized LAMA for COPD. For people who have difficulty using handheld inhalers, whether due to arthritis, poor coordination, or severe breathlessness, the nebulizer format can be a practical advantage. You simply breathe normally through the mouthpiece while the machine converts the liquid medication into a fine mist.
It’s important to know that Yupelri is strictly a maintenance medication. It is not a rescue inhaler and should not be used during a sudden breathing emergency. Acute symptoms still require a short-acting rescue medication.
Common Side Effects
Because Yupelri is an anticholinergic drug rather than a steroid, its side effect profile looks different from what you’d expect with corticosteroids. You won’t see steroid-related issues like oral thrush, hoarseness, or increased pneumonia risk. Instead, the most commonly reported side effects include headache, back pain, and cold-like symptoms such as a runny nose, sneezing, cough, or sore throat.
The anticholinergic mechanism does carry specific warnings. Blocking muscarinic receptors can affect the eyes and bladder in some people, so those with narrow-angle glaucoma, an enlarged prostate, or existing urination problems should discuss these risks before starting treatment. Signs to watch for include blurred vision, eye pain, seeing halos around lights, painful urination, or a noticeably weak urine stream. The drug’s terminal half-life ranges from 22 to 70 hours, meaning it stays active in the body for a considerable time after each dose.
Where Yupelri Fits in COPD Treatment
COPD treatment follows a stepped approach based on how severe your symptoms are and how often you experience flare-ups. For patients with frequent exacerbations but a relatively low day-to-day symptom burden, LAMA monotherapy is the preferred starting point. If symptoms aren’t adequately controlled, treatment can be escalated to a LAMA/LABA combination (adding a long-acting beta-agonist) before considering the addition of an inhaled corticosteroid. In other words, Yupelri often occupies a position in treatment where steroids aren’t yet necessary, and for some patients, steroids may never be added at all.
If you’re currently taking both Yupelri and an inhaled steroid, the two are doing separate jobs: the steroid is managing airway inflammation while the LAMA is keeping the muscles around your airways relaxed. Neither one replaces the other.